Pfizer's first quarter 2026 revenue of $14.5B beats estimates, driven by 22% growth in new and acquired products.

Pfizer reported first-quarter 2026 revenues of $14.5 billion, representing 2% year-over-year operational growth, and an adjusted diluted EPS of $0.75. The company reaffirmed its full-year 2026 financial guidance.

Key Highlights

• Excluding contributions from COVID-19 products Comirnaty and Paxlovid, revenues grew 7% operationally, highlighting the strength of the core business.
• The portfolio of launched and acquired products delivered 22% operational revenue growth, driven by key oncology drugs.
• The company reaffirmed its full-year 2026 guidance, including revenues in a range of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.